Calidi Biotherapeutics annual operating expenses
2021
2022
2023
2024
2025
Calidi Biotherapeutics Operating Expenses Growth & History (CLDI)
Calidi Biotherapeutics's operating expenses was $20.2M for fiscal 2025.
View full Calidi Biotherapeutics company overviewCalidi Biotherapeutics annual operating expenses history
| Fiscal year | Period ended | Operating expenses | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $20.2M | −$1.5M | −7.05% |
| 2024 | 2024-12-31 | $21.8M | −$7.2M | −24.89% |
| 2023 | 2023-12-31 | $29.0M | $5.8M | +25.11% |
| 2022 | 2022-12-31 | $23.2M | $21.4M | +1200.61% |
| 2021 | 2021-12-31 | $1.8M | — | — |
Calidi Biotherapeutics quarterly operating expenses
Q2.21
Q3.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Operating expenses | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $4.2M | −$1.5M | −26.73% |
| Q1 2026 | 2026-03-31 | $4.2M | −$875,000 | −17.29% |
| Q4 2025 | 2025-12-31 | $4.5M | $440,000 | +10.93% |
| Q3 2025 | 2025-09-30 | $5.0M | −$178,000 | −3.41% |
| Q2 2025 | 2025-06-30 | $5.7M | −$108,000 | −1.87% |
| Q1 2025 | 2025-03-31 | $5.1M | −$1.7M | −25.03% |
| Q4 2024 | 2024-12-31 | $4.0M | −$5.8M | −59.00% |
| Q3 2024 | 2024-09-30 | $5.2M | −$2.0M | −27.63% |
| Q2 2024 | 2024-06-30 | $5.8M | −$765,000 | −11.70% |
| Q1 2024 | 2024-03-31 | $6.8M | $1.3M | +24.71% |
| Q4 2023 | 2023-12-31 | $9.8M | −$5.5M | −35.80% |
| Q3 2023 | 2023-09-30 | $7.2M | $235,000 | +3.36% |
| Q2 2023 | 2023-06-30 | $6.5M | $6.2M | +1707.69% |
| Q1 2023 | 2023-03-31 | $5.4M | $4.9M | +923.72% |
| Q4 2022 | 2022-12-31 | $15.3M | — | — |
| Q3 2022 | 2022-09-30 | $7.0M | $5.9M | +538.06% |
| Q2 2022 | 2022-06-30 | $361,622 | $278,319 | +334.10% |
| Q1 2022 | 2022-03-31 | $528,858 | — | — |
| Q3 2021 | 2021-09-30 | $1.1M | — | — |
| Q2 2021 | 2021-06-30 | $83,303 | — | — |
Calidi Biotherapeutics operating expenses trends
Between the periods ended 2021-12-31 and 2025-12-31, Calidi Biotherapeutics's operating expenses increased from $1.8M to $20.2M, a change of $18.5M. The latest reported quarter, Q2 2026, shows $4.2M.
About the metric
What operating expenses mean
Operating expenses are the recurring costs of running a company’s business beyond the direct costs used to calculate gross profit. They commonly include selling, general and administrative expenses, research and development, and other operating costs.
Calculation and source
SEC-reported and calculated operating expenses
TickerStat uses operating expenses reported in company SEC filings when available. When a separate total is unavailable, it calculates operating expenses as aligned gross profit minus operating income for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Calidi Biotherapeutics source filings ↗